How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,932 results for

Osteoporosis Secondary to Medication

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

, Los Angeles Los Angeles, CA Nancy Lane, M.D. Director and Distinguished Professor Center for Musculoskeletal Health and Department of Internal Medicine University of California at Davis, School of Medicine Sacramento, California Jasvinder Singh, M.D., M.P.H. Division of Rheumatology University of Alabama Birmingham, AL vii Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Structured Abstract Objective. To summarize the effects of long-term (...) Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Comparative Effectiveness Review Number 218 RComparative Effectiveness Review Number 218 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600

2019 Effective Health Care Program (AHRQ)

2. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina

2018 Effective Health Care Program (AHRQ)

3. Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis Full Text available with Trip Pro

the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine (...) Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when

2016 Journal of endocrinological investigation

4. Impact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLS. (Abstract)

Impact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLS. Fracture Liaison Service (FLS) model for secondary prevention of fractures has demonstrated its cost-effectiveness using decision models. We analyze the impact of a FLS on pharmaceutical expenditures for osteoporosis (OP) in real-world circumstances.Expenditures on OP medications from January 2011 to January 2017 were compiled. Pharmaceutical expenditures (...) areas varied from 10.5% higher in the northern area pre-FLS to 11.2% post-FLS and 18.3% since March 2016. However, interrupted time series models do not find a significant impact of implementation of FLS on the pharmaceutical expenditures for either drug group.The implantation of an FLS did not lead to an increase in pharmaceutical expenditures for OP over the 5-year period compared to the standard care provided for secondary fracture preventions.

2018 Expert review of pharmacoeconomics & outcomes research

5. Perioperative Medical Complications after Posterior Approach Spinal Instrumentation Surgery for Osteoporotic Vertebral Collapse: A Comparative Study in Patients with Primary Osteoporosis and Those with Secondary Osteoporosis Full Text available with Trip Pro

Perioperative Medical Complications after Posterior Approach Spinal Instrumentation Surgery for Osteoporotic Vertebral Collapse: A Comparative Study in Patients with Primary Osteoporosis and Those with Secondary Osteoporosis A retrospective comparative study.To compare perioperative medical complications after posterior approach spinal instrumentation surgery for osteoporotic vertebral collapse (OVC) between patients with primary osteoporosis and those with secondary osteoporosis.With increased (...) were divided into primary (n=56) and secondary (n=35) osteoporosis groups. Bone mineral density (BMD), osteoporosis treatment prior to OVC, operative invasiveness, and perioperative medical complications were compared.Diabetes mellitus (51.4%) was the most common cause of secondary osteoporosis, followed by glucocorticoid use (22.9%). No significant differences were seen in terms of age, gender, BMD, osteoporosis treatment, or operative invasiveness, including the number of levels fused, estimated

2017 Asian spine journal

6. Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value

for their contributions to this report. ©Institute for Clinical and Economic Review, 2017 Page ii Evidence Report – Anabolic Therapies for Osteoporosis About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. ICER receives funding from government grants, non-profit foundations, health plans (...) strict conflict of interest guidelines and are convened to discuss the evidence summarized in ICER reports and vote on the comparative clinical effectiveness and value of medical interventions. More information about CTAF is available at https://icer- review.org/programs/ctaf/. ©Institute for Clinical and Economic Review, 2017 Page iii Evidence Report – Anabolic Therapies for Osteoporosis In the development of this report, ICER’s researchers consulted with several clinical experts, patients

2017 California Technology Assessment Forum

7. The use of combination therapy of parathyroid hormone analogues in combination with non-bisphosphonates drugs for the treatment of primary osteoporosis

The use of combination therapy of parathyroid hormone analogues in combination with non-bisphosphonates drugs for the treatment of primary osteoporosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors

2016 PROSPERO

8. Selection of anti-osteoporosis drugs in patients with osteoporosis during initial drug treatment

Selection of anti-osteoporosis drugs in patients with osteoporosis during initial drug treatment Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address (...) screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used

2018 PROSPERO

9. Osteoporosis Secondary to Medication

Secondary to Medication Osteoporosis Secondary to Medication Aka: Osteoporosis Secondary to Medication , Drug-Induced Osteoporosis , Medication Causes of Osteoporosis II. Causes: Anticonvulsants ral Anticonvulsants accelerate bone loss in elderly by 70% Agents that increase and sex steroid metabolism ( ) Phenobarbital Agents that increase renal calcium excretion References III. Causes: Endocrine and metabolic s (systemic and inhaled) See s ( , ) approaches 2.5 for use >8 months at excess doses (not when (...) Osteoporosis Secondary to Medication Osteoporosis Secondary to Medication Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Osteoporosis

2018 FP Notebook

10. Management of drug-induced immune and secondary autoimmune, haemolytic anaemia

Management of drug-induced immune and secondary autoimmune, haemolytic anaemia 1 Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia Quentin A Hill 1 , Robert Stamps 2 , Edwin Massey 3 , John D Grainger 4 , Drew Provan 5 and Anita Hill 1 on behalf of the British Society for Haematology. 1 Department of Haematology, Leeds Teaching Hospitals, 2 NHSBT, Sheffield, 3 NHSBT, Bristol, 4 Royal Manchester Children’s Hospital, University of Manchester (...) , Manchester, 5 Barts and The London School of Medicine and Dentistry, London Correspondence: BSH Secretary, British Society for Haematology, 100 White Lion Street, London, N1 9PF e-mail bshguidelines@b-s-h.org.uk KEYWORDS Autoimmune haemolytic anaemia, drug induced immune haemolytic anaemia, Evans syndrome, cancer, infection, systemic lupus erythematosus, common variable immunodeficiency, ulcerative colitis, transplantation. 2 SCOPE The objective of this guideline is to provide healthcare professionals

2016 British Committee for Standards in Haematology

11. Long term time trends in use of medications associated with risk of developing osteoporosis: Nationwide data for Denmark from 1999 to 2016. (Abstract)

Long term time trends in use of medications associated with risk of developing osteoporosis: Nationwide data for Denmark from 1999 to 2016. To evaluate the development in the use of medications associated with an increased risk of developing osteoporosis over the time period from 1999 to 2016.We extracted data on total sale, sales rate and usage rate for the medications of interest from www.medstat.dk, which is an online, open-source database reporting the monthly sale of both over-the-counter (...) and prescription-based medications in Denmark. The dataset covers both the primary and secondary health sectors.Most medications exhibited an increasing use from 1999 to 2016, though some had stable (e.g. glucocorticoids) or declining use. Notably, some medications showed widespread and increasing use, including proton pump inhibitors (PPI), selective serotonine reuptake inhibitors (SSRI) and venlafaxine. For PPI, sales rates increased by 461% from 1999 to 2016, with 9% of men and 11.4% of women filling

2018 Bone

12. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials. (Abstract)

Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials. To systematically evaluate the effects of bone anabolic therapies (BATs) - specifically, drug therapy with teriparatide, abaloparatide or romosozumab - on fractures, bone mineral density (BMD), and bone metabolites in postmenopausal osteoporosis.Six computerized engines were searched through to November 2018. We selected (...) randomized controlled trials (RCTs) evaluating the effect of BATs on postmenopausal osteoporosis and with at least 6 months of follow-up. Controls were placebo, no treatment, or bisphosphonates. Primary outcomes were vertebral and non-vertebral fractures. Secondary outcomes were: BMD determined by dual energy X-ray absorptiometry at total hip, lumbar spine, and femoral neck; N-terminal propeptide of type I procollagen (PINP); C-terminal telopeptide of type I collagen (CTX); and severe adverse events (SAE

2019 Maturitas

13. Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy

Krankenhaus Lutherhaus gGmbH Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the efficacy and safety of bisphosphonates in long term treatment of osteoporosis. Condition or disease Intervention/treatment Phase Osteoporosis Drug: Alendronate Drug: Placebo Phase 3 Detailed Description: Is a continued treatment with alendronate for another two years after a preceding therapy with bisphosphonates of at least four years able to reduce the incidence of new (...) in Osteoporotic Patients With Bisphosphonate Long Term Therapy Actual Study Start Date : February 2012 Actual Primary Completion Date : March 2013 Actual Study Completion Date : March 2013 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Alendronate Drug: Alendronate 70 mg per week Other Name: Fosamax Placebo Comparator: Placebo Drug: Placebo 1 pill per week Outcome Measures Go to Primary

2012 Clinical Trials

14. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. (Abstract)

Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. This study showed that bisphosphonate was safe and effective for the treatment of bone disorders in stage 4 chronic kidney disease (CKD) rats. Intermittent teriparatide therapy showed an anabolic action on bone even under secondary hyperparathyroidism conditions without having an adverse effect on mineral metabolism in late-stage (...) CKD.Patients with late-stage CKD are at high risk for fragility fractures. However, there are no consensus on the efficacy and safety of osteoporosis medications for patients with late-stage CKD. In the present study, we aimed to examine the efficacy and safety of alendronate (ALN) and teriparatide (TPD) for treating bone disorder in late-stage CKD with pre-existing secondary hyperparathyroidism using a rat model of CKD.Male 10-week-old Sprague-Dawley rats were subjected to a 5/6 nephrectomy or sham

2016 Osteoporosis International

15. Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial. (Abstract)

Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial. Despite their proven efficacy for secondary fracture prevention, long-term adherence with oral bisphosphonates is poor.To compare the effectiveness of two interventions on long-term oral bisphosphonate adherence after an upper extremity fragility fracture.Community-dwelling participants 50 years or older with upper extremity fragility fractures not previously (...) adherence compared to previously reported adherence rates in the general population, primary non-adherence and long-term adherence to bisphosphonates were similar in both arms. Adherence was influenced by family history of osteoporosis, satisfaction with current medical care, and income.ClinicalTrials.gov : NCT01401556.

2018 Osteoporosis International Controlled trial quality: predicted high

16. Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database Full Text available with Trip Pro

Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database This paper aims to compare the clinical effectiveness of oral anti-osteoporosis drugs based on the observed risk of fracture while on treatment in primary care actual practice.We investigated two primary care records databases covering UK National (...) Health Service (Clinical Practice Research Datalink, CPRD) and Catalan healthcare (Information System for Research in Primary Care, SIDIAP) patients during 1995-2014 and 2006-2014, respectivey. Treatment-naive incident users of anti-osteoporosis drugs were included and followed until treatment cessation, switching, death, transfer out, or study completion. We considered hip fracture while on treatment as main outcome and major osteoporotic fractures (hip, clinical spine, wrist, and proximal humerus

2018 Clinical epidemiology

17. Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials. Full Text available with Trip Pro

Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials. We aimed to determine whether the concomitant combination therapy of anabolic agents and bisphosphonates produces more effects on bone mineral density (BMD) than anabolic agents alone in patients with osteoporosis.We searched MEDLINE, EMBASE and the Cochrane Library for publications from 1 January 1980 to 1 August 2016 to identify all (...) the randomised controlled trials (RCTs) and quasi-RCTs. The primary outcome was the mean per cent changes in BMD at the lumbar spine, the total hip and the femoral neck with an optimal period of treatment (6 to 12 months). The secondary outcome was the mean per cent changes in BMD at the same sites with the full period of recommendation (18 to 24 months). A random-effects model was used to estimate the standardised mean differences (SMDs) and the 95% CIs.Seven studies, with 747 patients, were included

2018 BMJ open

18. Osteoporosis drugs for prevention of clinical fracture in postmenopausal women: a network meta-analysis of survival data

Osteoporosis drugs for prevention of clinical fracture in postmenopausal women: a network meta-analysis of survival data Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2019 PROSPERO

19. Interventions for managing medication-related osteonecrosis of the jaw. Full Text available with Trip Pro

Interventions for managing medication-related osteonecrosis of the jaw. Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab and antiangiogenic agents) and involves the progressive destruction of bone in the mandible or maxilla. Depending on the drug, its dosage, and the duration of exposure, the occurrence of this adverse (...) drug reaction may be rare (e.g. following the oral administration of bisphosphonate or denosumab treatments for osteoporosis, or antiangiogenic agent-targeted cancer treatment) or common (e.g. following intravenous bisphosphonate for cancer treatment). MRONJ is associated with significant morbidity, adversely affects quality of life (QoL), and is challenging to treat.To assess the effects of interventions versus no treatment, placebo, or an active control for the prophylaxis of MRONJ in people

2017 Cochrane

20. Medical Training to Achieve Competency in Lifestyle Counseling: An Essential Foundation for Prevention and Treatment of Cardiovascular Diseases and Other Chronic Medical Conditions: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

and prerequisite education for providers. Such a paradigm shift begins with medical education and adequate training. Medical schools have the opportunity to shape global health by incorporating lifestyle medicine as part of future physician preparation to practice medicine in the 21st century. The AHA is committed to supporting the transformation of medical education to achieve this goal. The goal of this scientific statement is to provide guidance in defining fundamentals in medical education and training (...) needed for future physicians to be proficient in lifestyle medicine. This writing group acknowledges that curricular design varies among medical schools and that a “one size fits all” model for lifestyle medical education is not practical or advantageous. This scientific statement focuses on key learning objectives (also referred to as learning outcomes in recent literature) that can be implemented as each medical school deems appropriate. Previous Statements and Recommendations In 2004

2016 American Heart Association

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>